About Ono

Our Products

OPDIVO® Intravenous Infusion KYPROLIS® for Intravenous Injection EMEND® Capsules
PROEMEND® for Intravenous Injection
GLACTIV® Tablets FORXIGA® Tablets KINEDAK® Tablets
PARSABIV® Intravenous Infusion RECALBON® Tablets ORENCIA® for Subcutaneous Injection
RIVASTACH® Patch ONOACT® for Intravenous Injection STAYBLA® Tablets
OPALMON® Tablets ONON® Capsules ONON® Dry Syrup
FOIPAN® Tablets

OPDIVO® Intravenous Infusion for Treatment of Malignant Tumor

OPDIVO® is a human anti-human PD-1 monoclonal antibody. PD-1 (programmed death-1), a receptor expressed on the surface of lymphocytes, plays a role in a regulatory pathway that suppresses activated lymphocytes in the body (negative signal). Available evidence suggests that cancer cells exploit this pathway to escape from immune responses. OPDIVO® is thought to provide benefit by blocking PD-1-mediated negative regulation of lymphocytes (i.e., the interaction of PD-1 with its ligands PD-L1 and PD-L2), thereby enhancing the ability of the immune system to recognize cancer cells as foreign and eliminate them. OPDIVO® is the world's first approved drug targeting PD-1.

FY 2016 Sales: 103.9 billion yen (Launched September 2014)

KYPROLIS® for Intravenous Injection

KYPROLIS® is in a class of drugs called proteasome inhibitors. Proteasome, an intra-cellular enzyme complex, functions to mediate degradation of polyubiquitinated proteins and control proliferation and differentiation of cells, as well as functional cell-death. It inhibits certain proteasome activity, thereby inducing functional cell-death of myeloma. KYPROLIS was launched on August 2016.

FY 2016 Sales: 2.0 billion yen (Launched August 2016)

EMEND® Capsules / PROEMEND® Intravenous Injection for the Treatment of Chemotherapy-induced Nausea and Vomiting

EMEND® is the first selective neurokinin (NK) 1 receptor antagonist in the world. The drug is effective for chemotherapy-induced nausea and vomiting.
In June 2012, an additional application for EMEND for pediatric patients aged 12 years and older was approved. Also, in March 2015, PROEMEND received additional approval for use in infants over 6months and in pediatric patients under 12-years of age.

FY 2016 Sales: 9.9 billion yen (Launched December 2009)

GLACTIV® Tablets for the Treatment of Type 2 Diabetes

GLACTIV®, a dipeptidyl-peptidase (DPP) 4 inhibitor, is an oral drug for treatment of type 2 diabetes. It regulates blood sugar levels in type 2 diabetes patients with the mechanism of action selectively inhibiting DPP-4, an enzyme which metabolites a gastrointestinal hormone, incretins. It thereby enhances the body's own insulin secretion ability in a glucose dependent manner and decreases glucagon release, signaling the liver to reduce its production of glucose.

FY 2016 Sales: 29.4 billion yen (Launched December 2009)

FORXIGA® Tablets for the Treatment of Type 2 Diabetes

FORXIGA® is a therapy that reduces blood sugar by excreting excess blood glucose via urine through the inhibition of SGLT2, a transporter that acts to regulate reabsorption of glucose in the kidney tubules. It is an oral drug for the treatment of type 2 diabetes and improves high blood sugar after meals and fasting blood sugar level, independently of insulin.

FY 2016 Sales: 7.8 billion yen (Launched May 2014)

KINEDAK® Tablets for the Treatment of Diabetic Peripheral Neuropathy

KINEDAK® is the first aldose reductase inhibitor marketed in Japan. By blocking aldose reductase which is activated under hyperglycemia, the drug reduces the production of sorbitol, which is involved in the development of neurological disorders associated with diabetes, and thereby alleviates accompanying symptoms such as numbness, pain and cramp in hands and feet and controls progress of the disease.

FY 2016 Sales: 2.9 billion yen

PARSABIV® Intravenous Infusion for Dialysis for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis

PARSABIV® reduces the excessive secretion of the parathyroid hormone by activating the calcium-sensing receptor in the parathyroid glands and lowers the phosphorus and serum calcium levels in the blood. It is an intravenous injection for dialysis patients to be administered through the dialysis circuit by the physician or medical staff upon completion of dialysis.

FY2016 Sales: 200 million yen(Launched February 2017)

RECALBON® Tablets for the Treatment of Osteoporosis

RECALBON®, a drug for the treatment of osteoporosis, is the first oral bisphosphonate discovered in Japan. It is one of the most potent bisphosphonates, rapidly preventing bone resorption, and is the first bisphosphonate that demonstrated significant effect in bone fracture prevention over placebo in Japanese osteoporosis patients. In September 2011, a Once Per 4 Weeks 50mg formulation was launched in addition to the Once-Daily 1mg formulation.

FY 2016 Sales: 11.3 billion yen (Launched April 2009)

ORENCIA® for Subcutaneous Injection for the Treatment of Rheumatoid Arthritis

ORENCIA® is the subcutaneous injection for the treatment of Rheumatoid Arthritis.
Rheumatoid arthritis is a condition where immune system attacks its own cells and tissues, and is known for inducing joint inflammation by the excessively produced cytokines. ORENCIA® is a biologic therapy that inhibits secretion of cytokines by blocking the signal which activates T cells, resulting in the easing of joint inflammation.

FY 2016 Sales: 11.6 billion yen (Launched August 2013)

RIVASTACH® Patch for the Treatment of Alzheimer's Disease

RIVASTACH® Patch is a transdermal patch for the treatment of Alzheimer's disease. It reduces the progression of deteriorating cognitive functions such as memory loss (forgetfulness) and disorientation (inability to recognizing time and place) by inhibiting acetylcholinesterase and thereby increasing the amount of acetylcholine in the brain and enhancing neurotransmission.

FY 2016 Sales: 8.9 billion yen (Launched July 2011)

ONOACT® for Intravenous Injection for the Treatment of Intra-operative or Post-operative Tachyarrhythmia, or Tachyarrhythmia in Left Ventricular Dysfunction

ONOACT® is a short-acting β1 blocker that selectively blocks β1 receptors mainly found in the heart. It is for emergency treatment of intra-operative or post-operative tachyarrhythmia (atrial fibrillation, atrial flutter, sinus tachycardia), and for treatment of tachyarrhythmia in left ventricular dysfunction (atrial fibrillation, atrial flutter).

FY 2016 Sales: 5.7 billion yen

Staybla® Tablets for the Treatment of Overactive Bladder (OAB)

Staybla® is an anticholinergic, an antagonist selectively binding to M3 and M1 muscarinic receptors. By reducing the excessive contraction of the smooth cells of the bladder, it is effective in symptoms associated with OAB including frequent urination, urinary incontinence, and urgency of urination. In April 2011, orally disintegrating tablets (OD tablets) were launched as additional formulation.

FY 2016 Sales: 4.8 billion yen (Launched June 2007)

OPALMON® Tablets for the Treatment of Peripheral Circulatory Disorder

OPALMON® is an orally administered prostaglandin-E1 derivative for the treatment of subjective symptoms and walking disability associated with acquired lumbar spinal canal stenosis and ischemic symptoms accompanying thromboangiitis obliterans. It improves symptoms caused by peripheral circulatory disorder such as numbness, pain or coldness of the hands or feet.

FY 2016 Sales: 17.0 billion yen

ONON® Capsules for the Treatment of Bronchial Asthma and Allergic Rhinitis

ONON® Capsules is a leukotriene receptor antagonist. Leukotriene is closely involved in the basic pathologies of bronchial asthma (airway inflammation, contraction, and hypersensitivity) and of allergic rhinitis. It relieves asthmatic symptoms, namely coughing, wheezing and breathlessness and rhinitis symptoms, namely sneezing, runny or blocked nose.

FY 2016 Sales: 6.8 billion yen

ONON® Dry Syrup for the Treatment of Bronchial Asthma and Allergic Rhinitis

ONON® Dry Syrup is a leukotriene receptor antagonist. Leukotriene is closely involved in the pathology of bronchial asthma (airway inflammation, contraction, and hypersensitivity). It is a dry syrup formulation, suitable for use with children. In December 2011, the additional indication for allergic rhinitis was approved.

FY 2016 Sales: 4.1billion yen

FOIPAN® Tablets for the Treatment of Chronic Pancreatitis and Postoperative Reflux Esophagitis

FOIPAN® Tablets inhibits pancreatic enzymes i which cause chronic pancreatitis and postoperative reflux esophagitis. It alleviates abdominal pain, nausea, tenderness and back pain due to the inflammation of the pancreas and relieves the symptoms and sensations after gastric operations, such as heartburn, backflow and cold or stinging feeling inside.

FY 2016 Sales: 3.8 billion yen